LAMZEDE J Code: J0217

Drug & Product Overview

HCPCS Descriptor Injection, velmanase alfa-tycv, 1 mg

HCPCS Added Date January 1, 2024

Manufacturer Chiesi USA

Route of Administration Intravenous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection, Powder, Lyophilized, For Solution

About LAMZEDE

Lamzede is a medication aligned to the HCPCS J Code: J0217 for billing, pricing, and reimbursement purposes in the United States. It is an Enzyme Replacement Therapy drug administered via the intravenous route and manufactured by Chiesi USA.

According to CMS Drug Use Information: Drug uses not available

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. Showing 1 of 2 NDCs — log in for the full crosswalk.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
10122-0180-02	Lamzede	Chiesi USA, Inc.	10	10 MG
•••••-••••-•• Log in to view	LAMZEDE

Login to view 1 more NDC package View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

LAMZEDE Pricing & Reimbursement

J0217 Private Payer Reimbursement

$467.37 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

LAMZEDE CPT Administration Codes

CPT Code	Description
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

LAMZEDE Medically Unlikely Edits (MUE)

The most billing units of J0217 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mg.

Practitioner Office & Hospital Outpatient

150 units / day

= 150 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

LAMZEDE Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

non-central nervous system manifestations of alpha-mannosidosis

Frequently Asked Questions

Is there an available Lamzede billing and coding guide?

Billing and coding information for LAMZEDE can be found through Chiesi USA,. Visit Here →

Are there any available Lamzede patient assistance programs?

LAMZEDE patient assistance information can be found through Chiesi USA,. Visit Here →

Where can I find Lamzede prescribing information?

LAMZEDE prescribing information can be found at the link below: Visit Here →

Where can I find Lamzede side effect information?

Information regarding LAMZEDE's side effects can be found at MedlinePlus Visit Here →

Does billing LAMZEDE require JZ/JW wastage modifiers?

CMS does not include LAMZEDE (J0217) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J0217. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.